Vertex Pharmaceuticals Inc. announced today that it submitted a New Drug Application to the U.S. Food and Drug Administration for the approval of the first triple-combination therapy for cystic fibrosis.
Site Search
Showing 1 - 10 of 86 results
News
|
May 6, 2011
|
1 min read
News
|
July 22, 2019
|
1 min read
News
|
Nov. 8, 2011
|
2 min read
Today, Vertex Pharmaceuticals Inc. released the initial Phase 3 clinical trial data for one of two next-generation, triple-combination modulators currently being tested.
News
|
Nov. 27, 2018
|
3 min read
News
|
March 4, 2011
|
2 min read
Phase 2 clinical trial results were announced today for a potential next-generation modulator to treat people with two copies of the most common cystic fibrosis mutation, F508del.
News
|
March 1, 2018
|
2 min read
A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells.
News
|
June 7, 2018
|
2 min read
News
|
Oct. 20, 2011
|
2 min read
Today Vertex Pharmaceuticals Inc. announced the two next-generation CFTR modulator candidates that will progress into Phase 3 clinical trials.
News
|
Jan. 31, 2018
|
4 min read
News
|
Oct. 25, 2011
|
2 min read